Sciensano

MAY 31, 2024

Each year, over 9,000 people die in Belgium as a result of smoking. These are the latest findings from Sciensano, Belgium’s public health institute. This represents one death every hour. Despite a clear decreasing trend in the number of smoking-related deaths, inequalities persist, with a greater impact among men and in Brussels and Wallonia. On World No Tobacco Day, Sciensano wants to draw more attention to the consequences of smoking.

111

111

Pharmaceutical Technology

MAY 31, 2024

The US FDA has granted RMAT designation for BlueRock Therapeutics' cell therapy, bemdaneprocel (BRT-DA01), for Parkinson's disease.

264

264

Bio Pharma Dive

MAY 31, 2024

Ahead of an advisory panel meeting, agency staff identified several sticking points in the clinical results backing Lykos’ ecstasy-based treatment for PTSD.

230

230

Pharmaceutical Technology

MAY 31, 2024

The EC has approved Biogen's QALSODY to treat adults with amyotrophic lateral sclerosis (ALS) linked to SOD1-ALS mutation.

147

147

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Bio Pharma Dive

MAY 31, 2024

Regeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over Keytruda and Neurocrine’s longtime CEO revealed plans to step down.

182

182

Fierce Pharma

MAY 31, 2024

With the FDA nod, Moderna's RSV vaccine becomes the company's second product to secure the FDA's backing.

Vaccine 130

Vaccine Vaccination Production 130

Fierce Pharma

MAY 31, 2024

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. | When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. But to Johnson & Johnson’s surprise, a subcutaneous formulation of its lung cancer med Rybrevant proved to work better than the original infusion.

Drugs 129

Drugs 129

Pharmaceutical Technology

MAY 31, 2024

Midland Pharmaceuticals has launched to focus on the development of a therapeutic for spinal cord injury and cerebrovascular disease.

Development 130

Development 130

Pharma Times

MAY 31, 2024

The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines

Vaccine 125

Vaccine Vaccination Clinical Trials Clinical Trials 125

Antidote

MAY 31, 2024

This Sunday, June 2, is National Cancer Survivors Day , designed to be a celebration for those who have survived cancer and an inspiration for those recently diagnosed. Since 1991, the national cancer death rate has dropped by 33% , partially due to advancements in treatment, early detection, and reduced smoking rates.

Research 119

Research 119

Advertisement

Clinical Supply

pharmaphorum

MAY 31, 2024

Moderna has secured FDA approval for its RSV vaccine, setting up a three-way market battle with GSK and Pfizer.

Vaccine 119

Vaccine Vaccination FDA Approval Marketing 119

Fierce Pharma

MAY 31, 2024

After Amgen’s KRAS confirmatory trial results were rejected by the FDA as uninterpretable, Bristol Myers Squibb has divulged details of its rival study. | Bristol Myers Squibb has divulged the details of Krazati's confirmatory trial. While the study doesn't share the same design problems as Amgen's rival KRAS program, it still leaves open questions about Krazati's regulatory outlook.

Trials 118

Trials 118

Pharma Times

MAY 31, 2024

The projects will focus on a range of research areas, including Down’s syndrome and ALS

Research 116

Research 116

Fierce Pharma

MAY 31, 2024

Just one week after Summit Therapeutics and Akeso’s bispecific antibody ivonescimab passed muster with Chinese regulators, the drug has pulled off another feat by staring down the PD-1 king Keytrud | In the phase 3 HARMONi-2 trial, solo ivonescimab delivered a statistically significant and clinically meaningful improvement in progression-free survival over Keytruda monotherapy.

Antibody 116

Antibody Trials Regulation Drugs 116

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

pharmaphorum

MAY 31, 2024

Stay updated with the latest clinical trials news from 27th to 31st May, featuring companies like Arcturus Therapeutics, AZ, Vesper Bio, Ultragenyx, and Incannex. Get insights into their latest developments and advancements in the field.

Clinical Trials 116

Clinical Trials Clinical Trials Trials Development 116

Intouch Solutions

MAY 31, 2024

EVERSANA INTOUCH takes pride in championing its employees. This month, we recognized and celebrated Asian American, Native Hawaiian and Pacific Islander (AANHPI) Heritage Month. Employees participated in various activities to spread awareness and honor AANHPI cultures. Jasmine Abraham, Account Supervisor, explained why celebrating AANHPI Heritage Month at EVERSANA INTOUCH is important.

105

105

pharmaphorum

MAY 31, 2024

Novartis’ Scemblix could be headed for first-line use in chronic myeloid leukaemia after outperforming TKI drugs in the ASC4FIRST study presented at ASCO.

Drugs 115

Drugs 115

Pharmaceutical Commerce

MAY 31, 2024

The latest news for pharma industry insiders.

Clinical Trials 104

Clinical Trials Clinical Trials Trials 104

Advertisement

Clinical Supply

pharmaphorum

MAY 31, 2024

Gilead's TROP2 ADC Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma.

Trials 110

Trials Clinical Trials Clinical Trials 110

Drug Patent Watch

MAY 31, 2024

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five… Source

Drugs 80

Drugs Branding Marketing 80

Fierce Pharma

MAY 31, 2024

Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to show an overall survival benefit in a lung cancer study. | Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to prove an overall survival benefit in a lung cancer study. Japan's Asahi Kasei is moving to buy rare disease drugmaker Calliditas for about $1 billion.

Trials 59

Trials 59

Drug Patent Watch

MAY 31, 2024

Brivaracetam is the generic ingredient in two branded drugs marketed by Ucb Inc, Aurobindo Pharma Ltd, Lupin Ltd, Sunshine, and Zydus Pharms and, and is included in seven NDAs.

Drugs 80

Drugs Branding Marketing 80

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Pharmaceutical Commerce

MAY 31, 2024

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

Antibody 52

Antibody Drugs 52

Drug Patent Watch

MAY 31, 2024

This chart shows the drugs with the most patents in Czech Republic.

Drugs 59

Drugs 59

Pharmaceutical Commerce

MAY 31, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Marketing 52

Marketing 52

Drug Patent Watch

MAY 31, 2024

Annual Drug Patent Expirations for ANGIOMAX+RTU Angiomax Rtu is a drug marketed by Maia Pharms Inc and is included in one NDA. It is available from three suppliers.

Drugs 59

Drugs Marketing 59

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

Fierce Pharma

MAY 31, 2024

A highly anticipated decision on Sanofi and Regeneron’s Dupixent to become the first biologic to treat chronic obstructive pulmonary disorder (COPD) is on hold in the United States but is speeding | A highly anticipated decision on Sanofi and Regeneron’s Dupixent to become the first biologic to treat chronic obstructive pulmonary disorder (COPD) is on hold in the United States but is speeding along in Europe.

Medicine 52

Medicine Production 52

Drug Patent Watch

MAY 31, 2024

Annual Drug Patent Expirations for WINLEVI Winlevi is a drug marketed by Sun Pharm and is included in one NDA. It is available from one supplier.

Drugs 59

Drugs Marketing 59

XTalks

MAY 31, 2024

Mercer and Marsh recently released its “ 2024 People Risk Report ,” which highlights critical areas for healthcare HR professionals. Understanding and addressing these risks is paramount as healthcare organizations navigate evolving challenges. Let’s delve into why these points are crucial for healthcare HR professionals, ensuring resilient and effective management of workforces.

HR 52

HR Compliance Containment Development 52

pharmaphorum

MAY 31, 2024

As AMR spreads globally, innovative startups are racing to develop solutions. Learn how Revagenix, LimmaTech and Lumen are using novel approaches to overcome AMR market failure.

Marketing 52

Marketing Development 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials